"There really is no safety risk with any non-live vaccine to our patients on biologics. And the vast majority of studies state that the efficacy of vaccines is maintained for patients on biologic therapy."

In a timely interview, Dr Mark Kirchhoff joins JCMS Editor in Chief Kirk Barber to discuss the impact of the rollout of COVID-19 vaccines on Dermatology patients, including a look at what vaccines are approved or will be approved in the near future, what immunotherapies are used in dermatology and what is the evidence of their effect on vaccinations, and what are the potential risks and efficacies of the COVID-19 vaccines for patients on immunotherapies. Dr Kirchhof's analysis is based on an extensive data review for publication.

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital.

JCMS Author Interviews is produced by David McGuffin of Explore Podcast Productions.

Theme music is by Lee Rosevere.